News brief­ing: Arv­inas shares dou­ble on in­ter­im da­ta for two can­cer pro­grams; UK bio­phar­ma snaps up on­col­o­gy CRO

Arv­inas $ARVN has new da­ta out on two of its pro­tein de­grad­er pro­grams, and in­vestors seemed thrilled with the news Mon­day morn­ing as shares dou­bled in ear­ly trad­ing.

The an­nounce­ment pro­vid­ed in­ter­im looks for ARV-471 and ARV-110, can­di­dates de­vel­oped us­ing the com­pa­ny’s Pro­tac plat­form. ARV-471 is in a Phase I study for lo­cal­ly ad­vanced or metasta­t­ic ER pos­i­tive / HER2 neg­a­tive breast can­cer, while ARV-110 is in the dose es­ca­la­tion por­tion of a Phase I/II tri­al in men with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER